Reason for request
Inclusion on the list of medicines reimbursed by National Insurance and approved for use by hospitals in the ‘Central neuropathic pain in adults’ indication extension.
Clinical Benefit
| Substantial |
The actual benefit of LYRICA in the treatment of central neuropathic pain in adults is substantial. |
Clinical Added Value
| no clinical added value |
Lyrica does not provide any improvement in actual benefit (IAB level V) over the usual management of central neuropathic pain in adults. |
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
bdshHJ60a8LvY45h
Listen
